GA
GANX.US Gain Therapeutics Inc
- Market cap
- USD 46.3M
- P/E
- -
- P/B
- 4.26x
- ROE
- -176.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GANX.US undervalued?
Graham numberThe Graham number of Gain Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gain Therapeutics Inc fundamental analysis
No fundamental analysis for Gain Therapeutics Inc yet.
Gain Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, …
Full company profileGain Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gain Therapeutics Inc annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 20.6K | 41.3K | 28.9K | 165K | 140K | 55.2K | 0.00 | 0.00 | - |
| Gross Profit | 20.6K | 41.3K | 28.9K | 165K | 140K | 55.2K | -84.1K | -94.0K | - |
| Operating Income | -1.03M | -2.10M | -3.48M | -13.8M | -17.8M | -22.3M | -20.4M | -18.7M | -17.7M |
| EBITDA | -1.03M | -2.10M | -3.47M | -13.9M | -17.4M | -22.1M | -19.8M | -19.2M | -17.4M |
| Net Income | -1.11M | -2.19M | -3.58M | -13.9M | -17.6M | -22.3M | -20.4M | -20.2M | -17.9M |
| EPS | -0.19 | -0.26 | -0.30 | -1.37 | -1.48 | -1.71 | -0.89 | -0.61 | -0.41 |
| Balance Sheet | |||||||||
| Total Assets | 812K | 660K | 9.60M | 39.0M | 24.1M | 18.6M | 12.1M | 22.8M | 13.2M |
| Total Liabilities | 1.76M | 1.11M | 3.40M | 4.17M | 5.22M | 6.03M | 4.78M | 4.25M | 3.08M |
| Shareholders' Equity | -951K | -450K | 6.20M | 34.8M | 18.9M | 12.6M | 7.34M | 18.6M | 10.2M |
| Cash & Short-term Investments | 401K | 303K | 7.49M | 36.9M | 20.1M | 16.8M | 10.4M | 20.8M | 11.7M |
| Total Debt | 1.31M | 201K | 1.26M | 1.61M | 1.27M | 1.03M | 653K | 732K | 677K |
| Cash Flow | |||||||||
| Operating Cash Flow | -745K | -1.87M | -3.24M | -12.4M | -14.7M | -18.9M | -18.9M | -18.5M | -16.6M |
| Capital Expenditure | 7.99K | 13.7K | 20.8K | 94.2K | 119K | 15.4K | 22.5K | 2.00 | 10.67 |
| Free Cash Flow | -753K | -1.88M | -3.26M | -12.5M | -14.8M | -18.9M | -18.9M | -18.5M | -16.6M |
| Ratios | |||||||||
| ROE | - | - | -57.7% | -39.9% | -93.2% | -177.0% | -278.1% | -108.6% | -176.6% |
| ROA | -136.2% | -332.2% | -37.3% | -35.6% | -73.0% | -119.7% | -168.4% | -88.4% | -135.5% |
| Net Profit Margin | -5,364.4% | -5,310.9% | -12,387.7% | -8,418.9% | -12,555.1% | -40,354.3% | - | - | - |
| Debt to Equity | - | - | 0.20x | 0.05x | 0.07x | 0.08x | 0.09x | 0.04x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Gain Therapeutics Inc dividends
Gain Therapeutics Inc has not paid dividends in the last 8 fiscal years.
Who owns Gain Therapeutics Inc
- Insiders 2.56%
- Institutions 18.84%
- Public & others 78.60%
- Shares outstanding 44.5M
- Free float 43.5M
Top funds holding GANX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BANOR SICAV Rosemary S EUR Acc | 300K | 0.69% | +20.03% | Sep 2026 |
| Fidelity Extended Market Index | 220K | 0.50% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 131K | 0.30% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 67.6K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 67.0K | 0.15% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 51.7K | 0.12% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 23.5K | 0.05% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 18.4K | 0.04% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 9.73K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding GANX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Marshall Wace Asset Management Ltd | 1.92M | 4.41% | +8.69% | Jun 2026 |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 1.14M | 2.61% | +100.00% | Jun 2026 |
| Potomac Capital Management, Inc. | 946K | 2.17% | -6.17% | Jun 2026 |
| GSA Capital Partners LLP | 632K | 1.45% | +102.30% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 609K | 1.39% | -3.65% | Jun 2026 |
| Vanguard Capital Management, LLC | 480K | 1.10% | +20.10% | Jun 2026 |
| Geode Capital Management, LLC | 454K | 1.04% | +1.38% | Jun 2026 |
| BlackRock Inc | 275K | 0.63% | +22.18% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 232K | 0.53% | +0.68% | Jun 2026 |
| UBS Group AG | 215K | 0.49% | -2.48% | Jun 2026 |
| Stratos Wealth Partners, LTD | 200K | 0.46% | +51.95% | Jun 2026 |
| Cresset Asset Management, LLC | 160K | 0.37% | 0.00% | Jun 2026 |
| State Street Corp | 158K | 0.36% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 155K | 0.35% | +520.58% | Jun 2026 |
| Squarepoint Ops LLC | 136K | 0.31% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 126K | 0.29% | -9.80% | Jun 2026 |
| LPL Financial Corp | 117K | 0.27% | +12.47% | Jun 2026 |
| Northern Trust Corp | 97.0K | 0.22% | -14.90% | Jun 2026 |
| Susquehanna International Group, LLP | 78.2K | 0.18% | -81.87% | Jun 2026 |
| Commonwealth Equity Services, LLC | 58.5K | 0.13% | +96.80% | Jun 2026 |
Gain Therapeutics Inc company profile
- Company name
- Gain Therapeutics Inc
- Ticker
- GANX.US
- Exchange
- USA Stocks
- Listed since
- Mar 18, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Fiscal year end
- December
- Address
- 4800 Montgomery Lane, Bethesda, MD, United States, 20814
- Phone
- 301 500 1556
- Website
- gaintherapeutics.com
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Gain Therapeutics Inc management
4- Dr. Khalid Islam Ph.D.Chairman & Founder · born 1955
- Mr. Gene Mack M.B.A.President, CEO, Director & Interim CFO · born 1974
- Dr. Terenzio Ignoni Pharm.D.Chief Operating Officer
- Dr. Joanne Taylor Ph.D.Chief Scientific Officer